As it awaits an FDA approval decision on apitegromab for spinal muscular atrophy, Scholar Rock is reshaping its leadership ...

Biohaven's $600M financing deal, Protara's cell therapy data, Pfizer's bladder cancer success, plus news from CG Oncology, ...

Boehringer Ingelheim's zongertinib shows promising results in lung cancer trial with 71% response rate and 14-month median ...

Vertex Pharmaceuticals, Amgen and Jazz Pharmaceuticals are among companies that received a positive opinion from European ...

France’s national public health agency is suspending immunization of adults 65 years and older with Valneva’s chikungunya ...

Globally, approximately 300 million people are grappling with obesity, a complex disease that has a profound impact on a ...

Merck's Keytruda shows 27% reduced risk of recurrence/death in head & neck cancer when used before & after surgery, with FDA ...

Revolution Medicines' zoldonrasib shows 61% response rate in lung cancer patients with KRAS G12D mutations in Phase 1 trial, ...

Merck KGaA said Monday it has inked a “definitive agreement” to acquire Pfizer spinout SpringWorks Therapeutics for an equity value of around $3.9 billion, rounding off several months of negotiations.

HHS Secretary Robert F. Kennedy Jr. said Friday that 35 states had signed up to participate in a new payment model meant to ...

Johnson & Johnson said its drug-device combo for bladder cancer achieved a high rate of complete responses lasting at least a ...

A federal district court in Texas on Thursday denied a request for a preliminary injunction from the Outsourcing Facilities ...